Loading clinical trials...
Loading clinical trials...
Medical Access Program for Patritumab Deruxtecan (HER3 DXd, U3-1402)
Conditions
Interventions
HER3-DXd
Locations
21
United States
Highlands Oncology
Springdale, Arkansas, United States
Southern California Permanente Medical Group
Los Angeles, California, United States
University of Colorado
Aurora, Colorado, United States
Yale-New Haven Hospital
New Haven, Connecticut, United States
Advent Health
Orlando, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Last Updated
June 8, 2025
Lead Sponsor
Daiichi Sankyo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions